Stay updated with breaking news from Aruvant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced the selection of an...
Share this article Share this article NEW YORK and BASEL, Switzerland, May 4, 2021 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced it has added eleven scientists to its manufacturing, preclinical and clinical teams, a major milestone in the company's strategy to build a beginning-to-end internal-external supply model led by its pioneering cell and gene therapy expertise. Additional expansion in clinical, technical, operational and quality areas will continue throughout the year as the company prepares for a pi...
Press release content from PR Newswire. The AP news staff was not involved in its creation. Aruvant Announces Oral Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting April 27, 2021 GMT (PRNewsfoto/Aruvant Sciences) NEW YORK and BASEL, Switzerland, April 27, 2021 /PRNewswire/ -- Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-1801, a potentially curative gene therapy for sickle cell disease (SCD), will be delivered in an oral presentation at the American Society of...
Share this article Share this article NEW YORK and BASEL, Switzerland, April 23, 2021 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced the appointment of Meghan Kelton, executive director, human resources (HR), and E. Blair Clark-Schoeb, senior vice president, communications, to the Aruvant leadership team. "Ms. Kelton's HR experience in gene therapy and Ms. Clark-Schoeb's public company and rare disease communications know-how will be critical as we take Aruvant to the next level," said Will Chou, M.D...
Press release content from PR Newswire. The AP news staff was not involved in its creation. Aruvant to Participate in Numerous Scientific and Investor Conferences in February and March February 11, 2021 GMT (PRNewsfoto/Aruvant Sciences) NEW YORK and BASEL, Switzerland, Feb. 11, 2021 /PRNewswire/ -- Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative gene therapies for the treatment of rare diseases, today announced management participation in multiple investor and scientific conferences in February and March. The company will be at the ...